Common Rule (United States)

Common Rule (United States)
Name	Common Rule
Country	United States
Enacted	1991 (codified)
Administered by	Department of Health and Human Services, Office for Human Research Protections
Related legislation	Belmont Report, National Research Act, Food and Drug Administration regulations

Common Rule (United States) is the common name for the federal policy regarding protection of human subjects in research, codified in multiple federal regulations and implemented by agencies such as the Department of Health and Human Services and the Food and Drug Administration. The Rule draws on ethical frameworks from the Belmont Report and historical events including the Nuremberg Trials and the Tuskegee Syphilis Study, and it informs oversight by Institutional Review Boards at universities, hospitals, and private research organizations. It establishes baseline standards for informed consent, institutional review, and protections for vulnerable populations across federally funded research programs at institutions like Harvard University, Johns Hopkins University, and the National Institutes of Health.

History

The Rule emerged from a lineage of policy responses to ethical controversies exemplified by the Nuremberg Trials, the Tuskegee Syphilis Study, and debates in the National Research Act deliberations, shaped by the Belmont Report and administrative actions by the Department of Health and Human Services, the Food and Drug Administration, and the Office for Human Research Protections. Early developments involved congressional hearings in the United States Congress, advisory reports from the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, and implementation guidance influenced by rulings in cases such as United States v. Stanley and administrative decisions by the Office of Management and Budget. Subsequent codification in the Code of Federal Regulations and interagency coordination with agencies including the Centers for Disease Control and Prevention, National Science Foundation, and Department of Defense created an interoperable regulatory framework applied at institutions like the University of California system and the Mayo Clinic.

Scope and Definitions

The Rule defines "human subject" and "research" for application across federally funded programs administered by HHS, FDA, NIH, and agencies such as the Department of Veterans Affairs, setting jurisdictional boundaries for universities, medical centers, and independent research organizations. Definitions reference categories of research activities including clinical trials overseen by institutional review boards at academic centers such as Columbia University, Stanford University, and the University of Pennsylvania, as well as social and behavioral research supported by the National Science Foundation and foundations like the Ford Foundation. The Rule delineates exclusions and exemptions that interact with policies from the Office for Human Research Protections, the National Institutes of Health, and regulatory guidance issued by the Federal Register.

Key Provisions and Requirements

Key provisions require informed consent procedures reflecting principles from the Belmont Report, documentation and recordkeeping consistent with Code of Federal Regulations provisions, and risk-benefit assessment standards used in trials funded by the National Institutes of Health, Department of Defense, and Veterans Health Administration. The Rule mandates requirements for expedited review categories, continuing review, and criteria for waivers that intersect with practices at medical centers such as Massachusetts General Hospital, Cleveland Clinic, and academic institutions like Yale University and Princeton University. Protections for vulnerable groups reference special considerations from guidelines influenced by the World Medical Association and ethical analyses tied to events such as the Declaration of Helsinki and advisory opinions from the Presidential Commission for the Study of Bioethical Issues.

Institutional Review Boards

Institutional Review Boards are central to implementation, operating under registration and reporting requirements overseen by the Office for Human Research Protections and collaborating with IRBs at institutions including the University of Michigan, Duke University, and University of Chicago. IRBs evaluate protocols for compliance with consent requirements, conflict-of-interest policies reflected in guidelines from the Association of American Medical Colleges, and data privacy safeguards that intersect with standards from the Health Insurance Portability and Accountability Act and research agreements with entities like the World Health Organization. Composition, quorum, and expertise standards mirror expectations found in institutional policies at Emory University, UCLA, and Boston University.

Compliance and Enforcement

Enforcement mechanisms include administrative actions by HHS agencies, investigational holds by the Food and Drug Administration, and funding restrictions by the National Institutes of Health and the National Science Foundation, with oversight interactions involving the Office of Inspector General and congressional oversight committees. Noncompliance can lead to corrective actions at institutions such as universities, medical centers, and contract research organizations, and may prompt civil litigation in federal courts or policy reviews by advisory bodies like the Presidential Commission and Government Accountability Office. Compliance programs often incorporate training modules developed with partners including the Collaborative Institutional Training Initiative and professional societies like the American Medical Association.

Revisions and Amendments

Revisions to the Rule have been promulgated through notice-and-comment rulemaking in the Federal Register, with major updates in parallel to initiatives from HHS, the Office for Human Research Protections, and interagency coordination with FDA and NIH, affected by stakeholder input from academic associations such as the Association of American Universities and research consortia. Amendments addressed topics like single IRB mandates for multi-site studies, informed consent modernization, and exemption category adjustments influenced by policy debates involving the National Academies of Sciences, Engineering, and Medicine and legal analysis cited in scholarship from Harvard Law School and Yale Law School.

Impact and Criticism

The Rule has influenced research practices at institutions including Johns Hopkins Hospital, Stanford Medicine, and the Cleveland Clinic, contributing to standardized protections in clinical research networks, cooperative trials coordinated by the National Cancer Institute, and social science projects funded by NSF. Critics from academic commentators at Columbia University, public-interest advocates, and legal scholars at Georgetown University and the Brennan Center have argued that regulatory complexity imposes administrative burdens, potentially slowing innovation and disadvantaging small institutions and independent investigators, while proponents cite improved participant protections and ethical oversight aligned with standards from the World Health Organization and international regulatory harmonization efforts.

Category:United States federal policy